These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 3368797)

  • 1. Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen.
    Bonomi P; Gale M; Von Roenn J; Anderson K; Johnson P; Wolter J; Economou S
    Semin Oncol; 1988 Apr; 15(2 Suppl 1):26-33. PubMed ID: 3368797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Megestrol acetate as primary hormonal therapy for advanced breast cancer.
    Johnson PA; Muss H; Bonomi P; Von Roenn J; Wolter J; Paschold E; Black W; Cooper M
    Semin Oncol; 1988 Apr; 15(2 Suppl 1):34-7. PubMed ID: 3368798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
    Ravdin PM; Green S; Dorr TM; McGuire WL; Fabian C; Pugh RP; Carter RD; Rivkin SE; Borst JR; Belt RJ
    J Clin Oncol; 1992 Aug; 10(8):1284-91. PubMed ID: 1634918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary hormonal therapy of advanced breast cancer with megestrol acetate: predictive value of estrogen receptor and progesterone receptor levels.
    Bonomi P; Johnson P; Anderson K; Wolter J; Bunting N; Strauss A; Roseman D; Shorey W; Economou S
    Semin Oncol; 1985 Mar; 12(1 Suppl 1):48-54. PubMed ID: 3975653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response.
    Ettinger DS; Allegra J; Bertino JR; Bonomi P; Browder H; Byrne P; Carpenter J; Catalano R; Creech R; Dana B
    Semin Oncol; 1986 Dec; 13(4 Suppl 4):9-14. PubMed ID: 3026052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progesterone receptor level as a predictor of response to megestrol acetate in advanced breast cancer: a retrospective study.
    Johnson PA; Bonomi PD; Anderson KM; Wolter JM; Bacon LD; Rossof AH; Economou SG
    Cancer Treat Rep; 1983; 67(7-8):717-20. PubMed ID: 6871887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association.
    Muss HB; Wells HB; Paschold EH; Black WR; Cooper MR; Capizzi RL; Christian R; Cruz JM; Jackson DV; Powell BL
    J Clin Oncol; 1988 Jul; 6(7):1098-106. PubMed ID: 3292710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients.
    Morgan LR
    Semin Oncol; 1985 Mar; 12(1 Suppl 1):43-7. PubMed ID: 3975652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials.
    Dhodapkar MV; Ingle JN; Cha SS; Mailliard JA; Wieand HS
    Cancer; 1996 Feb; 77(4):683-90. PubMed ID: 8616760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of megestrol acetate with or without premarin in the treatment of potentially responsive metastatic breast cancer. A Study of the Eastern Cooperative Oncology Group (E2185).
    Cobau CD; Declercq K; Neuberg D; Ingle JN; Tormey DC
    Cancer; 1996 Feb; 77(3):483-9. PubMed ID: 8630955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group.
    Fernö M; Stål O; Baldetorp B; Hatschek T; Källström AC; Malmström P; Nordenskjöld B; Rydën S
    Breast Cancer Res Treat; 2000 Jan; 59(1):69-76. PubMed ID: 10752681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential hormone therapy for advanced breast cancer.
    Von Roenn JH; Bonomi PD; Gale M; Anderson KM; Wolter JM; Economou SG
    Semin Oncol; 1988 Apr; 15(2 Suppl 1):38-43. PubMed ID: 3368799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
    Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Megestrol acetate v tamoxifen in advanced breast cancer: a phase III trial of the Piedmont Oncology Association (POA).
    Muss HB; Paschold EH; Black WR; Cooper MR; Capizzi RL; Christian R; Cruz JM; Jackson DV; Stuart JJ; Richards F
    Semin Oncol; 1985 Mar; 12(1 Suppl 1):55-61. PubMed ID: 3883503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
    Leitzel K; Teramoto Y; Konrad K; Chinchilli VM; Volas G; Grossberg H; Harvey H; Demers L; Lipton A
    J Clin Oncol; 1995 May; 13(5):1129-35. PubMed ID: 7738618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy.
    Robertson JF; Williams MR; Todd J; Nicholson RI; Morgan DA; Blamey RW
    Eur J Cancer Clin Oncol; 1989 Mar; 25(3):469-75. PubMed ID: 2703001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.
    Birrell SN; Roder DM; Horsfall DJ; Bentel JM; Tilley WD
    J Clin Oncol; 1995 Jul; 13(7):1572-7. PubMed ID: 7602345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of estrogen and progesterone receptors in epithelial ovarian cancer.
    Rose PG; Reale FR; Longcope C; Hunter RE
    Obstet Gynecol; 1990 Aug; 76(2):258-63. PubMed ID: 2371031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
    J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients.
    Vollenweider-Zerargui L; Barrelet L; Wong Y; Lemarchand-Béraud T; Gómez F
    Cancer; 1986 Mar; 57(6):1171-80. PubMed ID: 3943040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.